NCT03329950 2024-03-28A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced MalignanciesCelldex TherapeuticsPhase 1 Completed132 enrolled
NCT03999658 2023-05-01A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory MalignanciesSorrento Therapeutics, Inc.Phase 2 Withdrawn
NCT03027284 2020-05-19A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic CancerEli Lilly and CompanyPhase 1 Completed19 enrolled